65
Participants
Start Date
May 15, 2020
Primary Completion Date
September 30, 2027
Study Completion Date
January 31, 2028
RP1, intra-tumoral injection, oncolytic virus
Genetically modified herpes simplex type 1 virus
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Rochester Dermatologic Surgery, New York
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
NOT_YET_RECRUITING
Inova Schar Cancer Institute, Fairfax
WITHDRAWN
VCU Massey Cancer Center, Richmond
RECRUITING
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
RECRUITING
Duke University, Durham
RECRUITING
Mayo Clinic Florida, Jacksonville
RECRUITING
University of Miami Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Tennessee Medical Center at Knoxville, Knoxville
RECRUITING
The Ohio State University Comprehensive Cancer Center, Columbus
RECRUITING
The Cleveland Clinic Foundation, Cleveland
RECRUITING
University of Cincinnati, Cincinnati
WITHDRAWN
University of Michigan, Ann Arbor
RECRUITING
Mayo Clinic Rochester, Rochester
RECRUITING
University of Chicago, Chicago
RECRUITING
Washington University in St. Louis, St Louis
RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
University of Colorado Cancer Center School of Medicine, Aurora
RECRUITING
Medical Dermatology Specialists, Phoenix
RECRUITING
Mayo Clinic Arizona, Phoenix
RECRUITING
University of California, Los Angeles, Los Angeles
RECRUITING
University of California, San Diego, La Jolla
RECRUITING
UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Dana Farber Cancer Institute, Boston
Replimune Inc.
INDUSTRY